Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methotrexate vs Paclitaxel in Cisplatin-Ineligible Advanced Head and Neck Cancer
NCT00003592Phase 3Completed
- Sponsor
- Eastern Cooperative Oncology Group
- Start
- Apr 1999
- Primary completion
- Aug 2000
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of paclitaxel in squamous cell carcinoma of the head and neck (HNSCC) (2 arms), sponsored by Eastern Cooperative Oncology Group. Primary endpoints: Progression-Free Survival, Median Survival and 1 more. Started Apr 1999; status: completed.
02
Drugs
paclitaxel
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT00003592.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003592.